46218
document
Dose-response relationship of sertindole and haloperidol using the pharmacopsychometric triangle . OBJECTIVE Renewed insight into dose-related effects of sertindole and haloperidol was sought by re-analysing published data for antipsychotic effect , extrapyramidal effect , and patient wellbeing - i.e. , the important pharmacopsychometric triangle domains . METHOD Selected Positive and Negative Syndrome Scale ( PANSS ) subscales and the Simpson-Angus scale were tested for validity . Standardized effect sizes [ last observation carried forward ( LOCF ) ] at endpoint were calculated . RESULTS The scales were found to be valid instruments . The PANSS ( 11 ) psychotic subscale showed clinically significant effect sizes for all doses of sertindole ( 12 , 20 , and 24 mg ) and haloperidol ( 4 , 8 , and 16 mg ) . Extrapyramidal effects were evident for all doses of haloperidol , but absent for the lower doses of sertindole . The PANSS ( 6 ) depression subscale , a proxy measure of quality of life , showed a clinically significant effect for sertindole 20 mg and no effect for haloperidol . CONCLUSION This re-analysis confirmed the antipsychotic effect and absence of extrapyramidal effects for sertindole and , in addition , showed a clinically significant antidepressant effect . A profile for bipolar states emerged .
46219
Intervention_Pharmacological
sertindole
46220
Intervention_Pharmacological
haloperidol
46221
Intervention_Pharmacological
sertindole
46222
Intervention_Pharmacological
haloperidol
46223
Intervention_Pharmacological
sertindole
46224
Intervention_Pharmacological
haloperidol
46225
Intervention_Pharmacological
haloperidol
46226
Intervention_Pharmacological
sertindole
46227
Intervention_Pharmacological
sertindole
46228
Intervention_Pharmacological
haloperidol
46229
Intervention_Pharmacological
sertindole
46230
Outcome_Other
effect sizes
46231
Outcome_Other
Extrapyramidal effects
46232
Outcome_Other
quality of life
46233
Participant_Condition
Dose-response relationship of sertindole and haloperidol using the pharmacopsychometric triangle
46234
Participant_Condition
Selected Positive and Negative Syndrome Scale ( PANSS )